Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) EBIT (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed EBIT for 7 consecutive years, with -$97.9 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT fell 21.23% to -$97.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$349.4 million, a 33.54% decrease, with the full-year FY2025 number at -$349.4 million, down 33.54% from a year prior.
  • EBIT was -$97.9 million for Q4 2025 at Kymera Therapeutics, down from -$92.5 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$13.2 million in Q1 2021 to a low of -$97.9 million in Q4 2025.
  • A 5-year average of -$54.2 million and a median of -$48.1 million in 2023 define the central range for EBIT.
  • Peak YoY movement for EBIT: soared 50.01% in 2023, then tumbled 318.16% in 2024.
  • Kymera Therapeutics' EBIT stood at -$24.7 million in 2021, then tumbled by 56.21% to -$38.6 million in 2022, then skyrocketed by 50.01% to -$19.3 million in 2023, then crashed by 318.16% to -$80.8 million in 2024, then dropped by 21.23% to -$97.9 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's EBIT are -$97.9 million (Q4 2025), -$92.5 million (Q3 2025), and -$84.6 million (Q2 2025).